142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

314571
Take as directed: Opportunities for improving the medication experience of patients with chronic cardiovascular conditions

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Tuesday, November 18, 2014 : 3:10 PM - 3:30 PM

Özlem H. Ersin, MBA, MEd, PhD , Department of Pharmaceutical Sciences, Manchester University College of Pharmacy, Fort Wayne, IN
Mary E. Kiersma, PharmD, PhD , Accreditation Countil for Pharmacy Education (ACPE), Chicago, IL
This randomized prospective controlled study examined medication adherence behavior among non-valvular atrial fibrillation patients who were prescribed dabigatran, a twice daily prophylactic anticoagulant therapy to prevent stroke. Patients were identified through medical records. Each patient in the intervention group gained access to their health information through an electronic personal health record (ePHR) and received one-on-one training on the use of the ePHR. In addition, patients in the intervention group received educational newsletters with detailed information about dabigatran through their ePHR at 4, 6 and 10 weeks from enrollment. We present findings from patient focus groups as related to their medication adherence and the perceived impact of ePHRs on positive health behaviors.

Learning Areas:

Chronic disease management and prevention
Public health or related laws, regulations, standards, or guidelines

Learning Objectives:
Define the concept of Medication Adherence Discuss a technology-based innovation to improve adherence

Keyword(s): Drug Abuse Prevention and Safety, Chronic Disease Management and Care

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the co-PI on a study that explores medication adherence among patients on chronic medications.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.